AUG 10, 2026 · PHASE 3 TRIAL
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
ClinicalTrials.gov
Phase IIIb registration record with no results posted; describes planned enrollment and primary outcome measure only, without efficacy or safety data.
Reported
PhasePHASE3
Estimated enrollment150
Primary outcome measureTime to next treatment (TTNT), followed fro…